This article is more than 5 years old. Information may no longer be current.
Anti-VEGF may not improve BCVA in CNV complicating geographic atrophy
Click Here to Manage Email Alerts
Intravitreal ranibizumab may be not be effective at improving best corrected visual acuity in patients with choroidal neovascularization complicating geographic atrophy, according to a study.
The retrospective, interventional case series included 21 treatment-naïve eyes of 21 consecutive patients with geographic atrophy due to age-related macular degeneration. All eyes were treated with intravitreal Lucentis (ranibizumab, Genentech) for the development of CNV at least 24 months earlier. The mean number of ranibizumab injections was 5 ± 0.87 over the 24 months.
BCVA between baseline and 24 months of follow-up was significantly correlated (P < .0001). Baseline BCVA was improved at 3 months but not significantly; however, BCVA worsened from baseline (0.73 ± 0.05 logMAR) to 24 months (0.88 ± 0.08 logMAR) (P = .01).
There was a significant increase in geographic atrophy area at the last visit (P = .003).
Click Here to Manage Email Alerts